Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77


Identification of pluripotent and adult stem cell genes unrelated to cell cycle and associated with poor prognosis in multiple myeloma.

Kassambara A, Hose D, Moreaux J, Rème T, Torrent J, Rossi JF, Goldschmidt H, Klein B.

PLoS One. 2012;7(7):e42161. doi: 10.1371/journal.pone.0042161.


Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.

Hose D, Rème T, Hielscher T, Moreaux J, Messner T, Seckinger A, Benner A, Shaughnessy JD Jr, Barlogie B, Zhou Y, Hillengass J, Bertsch U, Neben K, Möhler T, Rossi JF, Jauch A, Klein B, Goldschmidt H.

Haematologica. 2011 Jan;96(1):87-95. doi: 10.3324/haematol.2010.030296.


Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome.

Decaux O, Lodé L, Magrangeas F, Charbonnel C, Gouraud W, Jézéquel P, Attal M, Harousseau JL, Moreau P, Bataille R, Campion L, Avet-Loiseau H, Minvielle S; Intergroupe Francophone du Myélome..

J Clin Oncol. 2008 Oct 10;26(29):4798-805. doi: 10.1200/JCO.2007.13.8545.


Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays.

Mahtouk K, Moreaux J, Hose D, Rème T, Meissner T, Jourdan M, Rossi JF, Pals ST, Goldschmidt H, Klein B.

BMC Cancer. 2010 May 13;10:198. doi: 10.1186/1471-2407-10-198.


Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma.

Kassambara A, Hose D, Moreaux J, Walker BA, Protopopov A, Reme T, Pellestor F, Pantesco V, Jauch A, Morgan G, Goldschmidt H, Klein B.

Haematologica. 2012 Apr;97(4):622-30. doi: 10.3324/haematol.2011.046821.


The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature.

Moreaux J, Cremer FW, Reme T, Raab M, Mahtouk K, Kaukel P, Pantesco V, De Vos J, Jourdan E, Jauch A, Legouffe E, Moos M, Fiol G, Goldschmidt H, Rossi JF, Hose D, Klein B.

Blood. 2005 Aug 1;106(3):1021-30.


Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.

Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, Anaissie E, Morris C, Muwalla F, van Rhee F, Fassas A, Crowley J, Tricot G, Barlogie B, Shaughnessy J Jr.

Blood. 2002 Mar 1;99(5):1745-57.


CD200 is a new prognostic factor in multiple myeloma.

Moreaux J, Hose D, Reme T, Jourdan E, Hundemer M, Legouffe E, Moine P, Bourin P, Moos M, Corre J, Möhler T, De Vos J, Rossi JF, Goldschmidt H, Klein B.

Blood. 2006 Dec 15;108(13):4194-7. Erratum in: Blood. 2007 Apr 1;109(7):2717.


Expression of genes encoding for proteins involved in heparan sulphate and chondroitin sulphate chain synthesis and modification in normal and malignant plasma cells.

Bret C, Hose D, Reme T, Sprynski AC, Mahtouk K, Schved JF, Quittet P, Rossi JF, Goldschmidt H, Klein B.

Br J Haematol. 2009 May;145(3):350-68. doi: 10.1111/j.1365-2141.2009.07633.x.


Gene expression of anti- and pro-apoptotic proteins in malignant and normal plasma cells.

Jourdan M, Reme T, Goldschmidt H, Fiol G, Pantesco V, De Vos J, Rossi JF, Hose D, Klein B.

Br J Haematol. 2009 Apr;145(1):45-58. doi: 10.1111/j.1365-2141.2008.07562.x.


Plasma cell myeloma--new biological insights and advances in therapy.

Barlogie B, Epstein J, Selvanayagam P, Alexanian R.

Blood. 1989 Mar;73(4):865-79. Review.


Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis.

Seckinger A, Meissner T, Moreaux J, Goldschmidt H, Fuhler GM, Benner A, Hundemer M, Rème T, Shaughnessy JD Jr, Barlogie B, Bertsch U, Hillengass J, Ho AD, Pantesco V, Jauch A, De Vos J, Rossi JF, Möhler T, Klein B, Hose D.

Oncogene. 2009 Nov 5;28(44):3866-79. doi: 10.1038/onc.2009.257.


Pluripotent embryonic stem cells and multipotent adult germline stem cells reveal similar transcriptomes including pluripotency-related genes.

Meyer S, Nolte J, Opitz L, Salinas-Riester G, Engel W.

Mol Hum Reprod. 2010 Nov;16(11):846-55. doi: 10.1093/molehr/gaq060.


Increased copy number of the interleukin-6 receptor gene is associated with adverse survival in multiple myeloma patients treated with autologous stem cell transplantation.

Kim SY, Min HJ, Park HK, Oh B, Kim TY, She CJ, Hwang SM, Kim M, Kim HK, Kim I, Yoon SS, Park S, Kim BK, Lee JH, Lee DS; Korea Multiple Myeloma Working Party..

Biol Blood Marrow Transplant. 2011 Jun;17(6):810-20. doi: 10.1016/j.bbmt.2011.01.002.


Low p27Kip1 expression is an independent adverse prognostic factor in patients with multiple myeloma.

Filipits M, Pohl G, Stranzl T, Kaufmann H, Ackermann J, Gisslinger H, Greinix H, Chott A, Drach J.

Clin Cancer Res. 2003 Feb;9(2):820-6.


Clinical and prognostic role of annexin A2 in multiple myeloma.

Seckinger A, Meissner T, Moreaux J, Depeweg D, Hillengass J, Hose K, Rème T, Rösen-Wolff A, Jauch A, Schnettler R, Ewerbeck V, Goldschmidt H, Klein B, Hose D.

Blood. 2012 Aug 2;120(5):1087-94. doi: 10.1182/blood-2012-03-415588.


Gene expression profiling and multiple myeloma.

Shaughnessy J Jr, Zhan F, Barlogie B, Stewart AK.

Best Pract Res Clin Haematol. 2005;18(4):537-52. Review.


Induction of angiogenesis by normal and malignant plasma cells.

Hose D, Moreaux J, Meissner T, Seckinger A, Goldschmidt H, Benner A, Mahtouk K, Hillengass J, Rème T, De Vos J, Hundemer M, Condomines M, Bertsch U, Rossi JF, Jauch A, Klein B, Möhler T.

Blood. 2009 Jul 2;114(1):128-43. doi: 10.1182/blood-2008-10-184226.


In vitro maintenance and retroviral transduction of human myeloma cells in long-term marrow cultures.

Stewart AK, Prince HM, Cappe D, Chu P, Lutzko C, Sutherland DR, Dubé ID.

Cancer Gene Ther. 1997 May-Jun;4(3):148-56.


Supplemental Content

Support Center